Lipidomics analysis of phosphatidylglycerol, cardiolipin, cholesterol and additional lipids. by Gary N. Landis (11475733)

Measurement of protein expression. by Eiman Y. Ibrahim (10731078)

“…</b> NCS1 levels over the course of 12 weeks of treatment. Western blot assessment of NCS1, using beta-actin as a loading control, in samples from patient white blood cells (n = 3 for weeks 0 and 6). …”

Oral antidiabetics. by Inmaculada Fierro (2188600)

“…As the rationale of the treatment is to achieve target glycemia levels, the appropriateness of the medications used is important. …”

Lipidomics analysis of major lipid classes. by Gary N. Landis (11475733)

Hep3B cell behavior experiments. by Qing-Gang Li (273341)

Table 1_Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy.doc by Qiqi Peng (6560057)

“…Evidently, these three patients demonstrated significant improvement in muscle strength and decrease of serum CK levels after efgartigimod treatment. …”

Discovery of <i>N</i>‑(1,3,4-Thiadiazol-2-yl)amide Derivatives as Uncompetitive Inhibitors of 6‑Phosphogluconate Dehydrogenase by Rong Zhang (44942)

“…Moreover, <b>19n</b> treatment could result in a decrease of NADPH and Ru-5-P production as well as DNA synthesis in A549 cells. …”

Ivermectin uptake and infection status (n = 270). by Mwanahawa I. Mshana (15460720)

“…<div><p>Onchocerciasis transmission in the Ulanga District of Morogoro-Tanzania is still ongoing despite more than 20 years of Community Directed Treatment with Ivermectin (CDTI) in the area. Even though surveys conducted over the years in the area have revealed a decrease in the prevalence of onchocerciasis, the prevalence of comorbidities suggested to be associated with this filarial infection, as epilepsy, is rising in endemic regions. …”

Flow chart of sampling technique. by Mwanahawa I. Mshana (15460720)

“…<div><p>Onchocerciasis transmission in the Ulanga District of Morogoro-Tanzania is still ongoing despite more than 20 years of Community Directed Treatment with Ivermectin (CDTI) in the area. Even though surveys conducted over the years in the area have revealed a decrease in the prevalence of onchocerciasis, the prevalence of comorbidities suggested to be associated with this filarial infection, as epilepsy, is rising in endemic regions. …”

The data set used for analysis. by Mwanahawa I. Mshana (15460720)

“…<div><p>Onchocerciasis transmission in the Ulanga District of Morogoro-Tanzania is still ongoing despite more than 20 years of Community Directed Treatment with Ivermectin (CDTI) in the area. Even though surveys conducted over the years in the area have revealed a decrease in the prevalence of onchocerciasis, the prevalence of comorbidities suggested to be associated with this filarial infection, as epilepsy, is rising in endemic regions. …”

Subgroup analysis. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Study outcomes. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Adverse events ^a. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Conclusions</p><p>Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.…”